Profiles and Reports

Profiles and Reports

Battelle Report on Economic Impact

The U.S. biopharmaceutical industry develops medicines that save, sustain and improve lives. The industry is also well recognized as a dynamic and innovative business sector generating high-quality jobs and powering economic output and exports for the U.S. economy. This report quantifies this economic impact of the biopharmaceutical sector on the U.S. economy and jobs. Using input/output analysis, this report measures the direct and indirect impacts of the biopharmaceutical sector, and quantifies the economic impacts that would occur if biopharmaceutical revenues increase or decrease from significant changes in the business operating environment.

Read the report.

 

Industry Profile 2014

The annual 2014 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.

Read the 2014 Industry profile

 

 

Chart Pack 

Our Chart Pack, “Biopharmaceuticals in Perspective,” contains useful facts and figures about prescription medicines and their role in the health care system, as well as in America's overall economy. Bookmark it today.

View the chartpack

 

 

Recognizing the Value of Innovation in HIV/AIDS Therapy 

A new white paper from Boston Healthcare Associates takes a closer look at the remarkable advances we’ve made in the treatment of HIV/AIDS. Progress against HIV/AIDS has occurred through a series of incremental gains in knowledge and discovery, transforming what was once considered an acute fatal illness into a manageable chronic condition for those who have access to treatment.

Read the report.
Read the executive summary.

 

Recognizing the Value of Innovation in Rheumatoid Arthritis 

A new white paper from Boston Healthcare Associates explores the various ways in which additional clinical value has been realized over time for RA patients. As our understanding of the underlying mechanism of the disease grows, and researchers accumulate knowledge regarding the real-world use of many therapies, the treatment paradigm has shifted from aiming for symptom relief to targeting disease remission.

Read the report.
Read the executive summary. 

 

 

Innovation in the Biopharmaceutical Pipeline: A Multidimensional View

A new study by the Analysis Group details how the U.S. biopharmaceutical industry leads the world in development of new medicines, with over 300 new prescription medicines approved by the U.S. Food and Drug Administration (FDA) over the past decade.

Read the report.

 

 

 

The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients 

This report contains a range of innovative new treatment approaches that have the potential to save lives and improve patient health.

Read the report.

 

 

 

Biopharmaceuticals in Medicare, Medicaid and Department of Veterans Affairs

This chart pack features key facts about prescription medicines in three major government programs Medicare, Medicaid and the Veterans Affairs (VA) drug benefit each provide drug coverage through different methods of administration

Read the report.

 

Recognizing Value In Oncology Innovation

A new white paper by Boston Healthcare Associates examines significant progress in the fight against cancer in the United States. Several organizations report declines in cancer death rates and increases in survival rates for both men and women. New medicines have accounted for 50-60 percent of the increase in cancer survival rates since 1975.

Read the report.

Read the executive summary.

 

 

 Growth Platform For Economies Around the World

A new study by the Battelle Technology Partnership Practice examines the increasing efforts by other countries to grow their economies by focusing on the biopharmaceutical sector and related industries.

Read the report.

Read the executive summary.

 

 

 

 Interactive 2012 Pharmaceutical Industry Profile 

Experience the 2012 Pharmaceutical Industry Profile in a new interactive format on your iPad. From your iPadclick here and download the interactive version. You can also download directly through iTunes here.

 

 

 

 

 

 
Driving State Economic Growth in the 21st Century: Advancing the Biopharmaceutical Sector

The biopharmaceutical industry contributes significantly to national, state, and local economies. Recognizing this sector’s contributions to state economies in terms of providing high‐value, high‐wage, revenue‐generating jobs, PhRMA commissioned Battelle to conduct this study to examine the extent to which state governments are targeting the industry for economic growth and development.

Read the executive summary.

Read the report.

 

 

 
Archstone Report on Economic Impact

Despite the economic challenges of recent years, America's biopharmaceutical research companies remain a major source of employment throughout the United States. The sector also contributes to the nation's economy in various ways, including contribution to GDP, taxes, R&D spending, intellectual property, and exports.

Read the report.

 

 

Discoverers Award 2011: JANUVIA®

Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., received the 2011 Discoverers Award, the highest honor from PhRMA. They were recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise.

Learn more about JANUVIA®.

 

 

 

Pharmaceutical Marketing & Promotion

Activities conducted as part of pharmaceutical marketing and promotion are an important part of informing consumers and healthcare professionals about new treatments. This booklet offers facts that we believe are important to consider as the value of marketing and promotion is debated.

Learn more about marketing & promotion.

 

 

 

 

New Medicines Approvals in 2012

In 2012, the Food and Drug Administration (FDA) approved 44 new medicines—the largest number in 15 years.  Among the medicines were 14 medicines for cancer and cancer-related conditions, including the first medicine approved to treat late-stage basal cell carcinoma (the most common form of skin cancer), three medicines for the treatment of leukemia, and two medicines for the treatment of late-stage colorectal cancer.

Read the report. 

 

 

 

More On PhRMA — powered by PhRMApedia